bought Selb on this news
10:42 AM EDT, 10/20/2020 (MT Newswires) -- Selecta Biosciences (SELB) and Asklepios BioPharmaceutical said Tuesday the US Food and Drug Administration has granted Rare Pediatric Disease Designation to its gene therapy candidate MMA-101 for the treatment of isolated methylmalonic acidemia, a disorder in which the body cannot break down some proteins and fats.
The designation allows a Sponsor who receives an approval for a product to potentially qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different
product.
and this news
October 21, 2020 10:46 AM ET (BZ Newswire) -- Biotech
Selecta Biosciences (NASDAQ:SELB) shares are trading higher on Wednesday potentially after its director Timothy Springer reported the purchase of 1,887,696 shares at an average price of $2.30 in a Form 4 filing in Tuesday's after hours.
Selecta Biosciences is a clinical-stage biopharmaceutical company. The company is engaged in using synthetic vaccine particle or SVP technology to discover and develop targeted therapies to modulate the immune system effectively and safely treat rare and serious diseases. It provides SVP for immune tolerance and stimulation.
The company products in Phase 1 and Phase 2 include SEL-403 for Pancreatic Cancer and Mesothelioma, SEL-212 for Chronic Severe Gout, SEL-302 for Methylmalonic Acidemia (MMA) and SEL-313 for Ornithine Transcarbamylase Deficiency (OTC).
News 
Market Data 
Discover 
